PDSB — PDS Biotechnology Cashflow Statement
0.000.00%
- $63.03m
- $43.17m
Annual cashflow statement for PDS Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.8 | -16.9 | -40.9 | -42.9 | -37.6 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 0.613 | 4.35 | 10.6 | 9.45 | 8.27 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.07 | 0.076 | 4.47 | -0.199 | -5.75 |
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -13.1 | -12.5 | -25.7 | -33.6 | -35 |
Capital Expenditures | — | — | — | — | -0.029 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | — | — | — | 0 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Cash from Investing Activities | 0 | — | — | — | -0.029 |
Financing Cash Flow Items | — | — | -0.72 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 29.8 | 48.9 | 34.3 | 16.4 | 20.2 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 16.7 | 36.4 | 8.58 | -17.3 | -14.9 |